Axa Girds for Nine-Month Update as Buyback, ICC Exit and RBC Trim Shape the Narrative

Axa will report nine-month activity on 29 October 2026, after a EUR 470.8m buyback, an AXA XL distribution change and the end of its ICC health contract.

Axa is counting down to 29 October 2026, when the Paris-based insurer will publish activity indicators for the first nine months of the year. The interim report will be the first broad gauge of how a series of operational reshuffles, capital measures and geopolitical complications have filtered through to the group's underlying momentum.

Ahead of that date, the company has kept busy on several fronts — redrawing responsibilities in its large-accounts and specialty operations, neutralising the dilution from a staff share scheme, and unwinding a high-profile institutional health insurance mandate.

New Distribution Chief for AXA XL

Within the AXA XL division, the group has opted for continuity in personnel while injecting fresh sales energy. Dr. Thomas Götting took over as Chief Client & Distribution Officer for the APAC & Europe region with effect from 1 October. He will oversee client and distribution activities across both the Asia-Pacific and European markets.

At the same time, Axa is broadening its offering through a dedicated unit. The launch of the AXA XL Excess & Surplus Lines Insurance Company creates a specialised vehicle aimed squarely at wholesale brokers.

Buyback to Offset Shareplan 2026

On the capital side, management is deploying targeted tools to shield shareholders from dilution. Axa agreed to repurchase and subsequently cancel its own shares for a maximum amount of EUR 470,800,000.

The move is designed to fully offset the issuance of new shares under the employee programme Shareplan 2026. The buyback is tightly scheduled and is to be completed no later than 29 October 2026.

ICC Health Contract Ends Amid Sanctions Concerns

International legal risk has also prompted adjustments to the portfolio. Axa and the International Criminal Court ended their existing health insurance contract by mutual agreement.

As Reuters reported, citing Financial Times coverage, the decision was linked to risks stemming from the extraterritorial application of US sanctions. A spokesperson for the court gave no official reasons for the move; the institution is switching to another insurer.

The episode illustrates how deeply geopolitical tensions can reach into the traditional insurance business. For Axa, the contract's end means the loss of a prominent institutional client — but it also shows how carefully international organisations are recalibrating their risk management against external sanctions threats.

RBC Trims Target, Keeps Outperform

Analysts have meanwhile made modest adjustments to their expectations. On 25 September, RBC Capital lowered its price target for Axa from EUR 54 to EUR 52, while leaving its rating unchanged at "Outperform." Despite the slight reduction, the firm continues to see the stock delivering an above-average performance.

Share Price Retreats Below Seven-Day Mark

Trading has been subdued for shareholders in recent sessions. The stock closed at EUR 41.96 on Friday, translating into a 5.2% decline over seven days. A separate seven-day reading put the drop at 5.5%.

Even after the pullback, the shares remain above their 200-day moving average of EUR 41.50. The stock also entered the autumn at a distance of 8.6% below its 52-week high.

Investors now have their sights set on the interim report at the end of the month, which will shed light on the group's earnings position.